1. Introduction {#sec1}
===============

Patients with a non-diagnostic bronchoendoscopic examination often undergo further invasive examinations. Bronchoendoscopy is relatively safe, with less than 1% of procedures complicated by pneumothorax [@bib1]. However bronchoendoscopic examination is not necessarily comfortable procedure and limited by its sensitivity, which ranges from 34 to 88%, depending on the location and size of the lesion [@bib2]. In this study, we report a case of lung cancer diagnosed by genomic analysis, but not by usual bronchoendoscopic examinations including cytological and pathological measures.

2. Case presentation {#sec2}
====================

A 72-year-old man was pointed out to have an abnormal mass lesion by computed tomography of the chest by a routine health check-up. He was referred to our hospital and underwent the clinical examinations and surgery. During these procedures, we collected several specimens for diagnosis and genomic analyses ([Table 1](#tbl1){ref-type="table"}).

The abnormal mass lesion was located in the upper lung field and the size of mass was 3.0 × 2.5 cm in diameter ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}). He had a smoking history of 50 pack-year. Interstitial lung fibrosis was also pointed out but he had no respiratory symptom. The result of laboratory examination of hematology and blood chemistry was within normal ranges including several tumor markers. Bronchoendoscopy was performed to confirm a diagnosis of the mass lesion. Because the introducible bronchus to mass lesion was not identified, we could not use endobronchial ultrasonography (EBUS) using a guided sheath (EBUS-GS) [@bib3]. Instead, by an angulated curette forceps, we obtained a small amount of liquid samples from bronchus adjacent to the mass lesion. We also obtained bronchial washing, bronchial brushing samples and sputum. A report from cytological examination of bronchial washing and curetted samples indicated there were no apparent tumor cells in these specimens (all "negative").

Imaging findings including local invasion to adjacent vessels and mediastinal nodal swelling was compatible with lung cancer as the stage of cT3N2M0 (stage IIIA) clinically. Because an innominate vessel was located over the tumor, we could not find the route of percutaneous CT guided needle biopsy ([Fig. 2](#fig2){ref-type="fig"}). Upper lung lobe resection was performed to confirm the diagnosis and the stage of the tumor. A pathological diagnosis of a resected tumor (3.0 × 2.5 cm) was solid type of adenocarcinoma by new WHO classification ([Fig. 3](#fig3){ref-type="fig"}) [@bib4]. After surgery, we could confirm the non-invasiveness of the tumor to adjacent innominate vessel and no mediastinal lymph node metastasis. (pT2aN0M0, stage IB). However, because of local recurrence of mediastinal lymph nodes metastases with malignant pleural effusion, radiation therapy and chemotherapy with carboplatin and nab-paclitaxel was administered as advanced stage of lung cancer.

Recent international collaborative studies from The Cancer Genome Atlas (TCGA) identified a set of 53 significantly mutated genes (SMGs) by studying the whole exons of 230 cases of lung adenocarcinoma and 178 of squamous cell carcinoma [@bib5], [@bib6]. Instead of analyzing approximately 20,000 genes of whole exons, these SMGs will be able to disclose principal mutations and signaling pathways in tumor. These 53 SMGs may be significant, and sufficient for the diagnosis and basic understanding of lung cancer-related oncogenes [@bib7]. In order to elucidate the utility of this genomic analysis for definite diagnosis of lung cancer, we performed targeted sequencing of the 53 lung cancer associated SMGs using an *in house* panel, which covers 205,684 base pairs and 95% of targeted regions (see [Table 2](#tbl2){ref-type="table"}) [@bib7].

We analyzed resected surgical specimens, bronchial washing, sputa and plasma using next generation sequencer (Ion Proton platform, Thermo Fisher Scientific, Waltham, MA, USA). Sequencing data was obtained by 4,623,928 mapping reads (range: 3,482,251--7,431,995) with 94.1% of reads aligned onto the targeted regions (range: 83%--97%) and with an average of 1669-fold coverage (range: 1271--2731) ([Table 3](#tbl3){ref-type="table"}). The analysis of resected primary tumor revealed two somatic mutations in *TP53* and *COBL*, namely, the former Gln317Ter, and the latter Pro828Thr, respectively ([Table 4](#tbl4){ref-type="table"}). The mutations found in supernatant of bronchial washing fluid, sputum and plasma were identical to those of tumor ([Table 4](#tbl4){ref-type="table"}). Of interest, we observed the concentration gradient of mutant allelic fraction (AF) ([Table 4](#tbl4){ref-type="table"}).

The AFs were highest, as was expected, in the primary tumor e.g., 82% and 15% at *TP53* Gln317Ter and *COBL* Pro828Thr, respectively ([Table 4](#tbl4){ref-type="table"}). The AFs of the two mutations were stepwisely decreased from bronchial washing supernatant, sputum and plasma ([Table 4](#tbl4){ref-type="table"}). In contrast, we could not confirm a diagnosis of lung cancer by conventional cytological and histological examinations.

3. Discussion {#sec3}
=============

When lung cancer was suspected, the method of EBUS-GS is useful for collecting samples from peripheral pulmonary lesions to yield high diagnostic accuracy (77%) [@bib3]. In this case, a peripheral mass lesion of 3.0 cm in diameter was located in mediastinal area of upper lung lobe, and several attempts to find out an introducible bronchus for EBUS-GS failed. However, we obtained curetted cytological samples and bronchial washing, but conventional cytological examinations were all reported "negative" or "non-diagnostic".

Genomic analysis was performed at our laboratory of GAC (Genome Analysis Center) established 3 years ago at our hospital [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]. We already developed lung cancer panel consisting of 53 genes [@bib7]. We tested whether it will be useful to detect lung SMGs in cytologically negative samples collected by bronchial washing.

Bronchial samples were usually collected from segmental bronchus connecting to peripheral nodules by bronchoendoscopy. If we were able to use EBUS-GS, we might have had specimens which contain more cellular component. That could have made conventional pathological and cytological diagnosis more informative. However, we were not able to find the leading bronchus to the nearest site of the tumor. We were only able to obtain a small amount of liquid samples probably far away the tumor. But still, we were able to obtain almost complete concordant results among the primary tumor, endobronchial washings, sputum and plasma with different concentrations ([Table 4](#tbl4){ref-type="table"}).

Evaluation of circulating tumor DNA in plasma/serum is a promising non-invasive diagnostic tool [@bib15]. Of particular interest in this case was that we were able to detect the same mutations in circulating plasma collected beforehand at initial evaluation by bronchoscopy, clearly indicating that we may not need cellular components which are pre-requisite for classical cytological diagnosis. This was also reflected that the mutations were detected in supernatant, but not in the cellular rich buffy coats ([Table 4](#tbl4){ref-type="table"}).

Because genomic analysis of sputum before bronchial washing by using an *in house* lung cancer panel was positive in this case, genomic analysis may have a possibility of non-invasive tool for the diagnosis of lung cancer in patients with negative cytological examinations. In a previous report from The Johns Hopkins Lung Cancer Project, *KRAS* or *TP53* mutation identical to primary lesion was also detected in the sputum by using a polymerase chain reaction-based assay [@bib16]. Lung cancer panel consisting of 53 genes used in this case may be more utilizing procedure to diagnose lung cancer. Experience of a large number of patients is needed to reach the final conclusion about the utility of genomic analysis as a non-invasive diagnostic tool.

4. Conclusion {#sec4}
=============

Genomic analysis by lung cancer panel consisting of 53 genes used in this case may have a possibility of a non-invasive diagnostic tool of lung cancer.
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![Chest radiography revealed a mass lesion in mediastinal right upper lung field. Tumor lesion was indicated by dotted circle.](gr1){#fig1}

![Computed tomography of the chest revealed a mass lesion adjacent to vessels in mediastinum. Tumor lesion was indicated by dotted circle. A) The introducible bronchus to mass lesion was not identified. B) Because an innominate vessel was located over the tumor, we could not find the route of percutaneous CT guided needle biopsy.](gr2){#fig2}

![A pathological diagnosis of a resected tumor was solid type of adenocarcinoma by new WHO classification.](gr3){#fig3}

###### 

The timeline of clinical examinations, collection of samples and genomic analyses was exhibited.

Table 1

  Date        Events                       Results
  ----------- ---------------------------- ----------------------------------------------
  5/26/2015   First visit                  Symptom free
  5/26/2015   Chest X-P                    A mass of right upper lung field was found.
  6/12/2015   Chest CT                     Local invasion to innominate vein was found.
  6/25/2015   Sputum Collection            No apparent tumor cells were detected.
              Bronchial brushing/washing   No apparent tumor cells were detected.
              Bronchial curetting          No apparent tumor cells were detected.
              Blood sample collection      Collection for genomic analysis
  7/7/2015    Bone Scintigraphy            No metastasis was found.
  7/8/2015    Brain MRI                    No metastasis was found.
  8/10/2015   Surgical Resection           No invasive findings were revealed.
  9/25/2015   Genomic analysis             

###### 

Lung cancer-associated 53 significantly mutated genes in targeted sequence panel.

Table 2

  Number of gene   Gene symbol   Chromosome   Number of amplicons   Total bases   Covered bases   Missed bases   Overall coverage
  ---------------- ------------- ------------ --------------------- ------------- --------------- -------------- ------------------
  1                *AKT1*        chr14        26                    1573          1497            76             95%
  2                *AKT2*        chr19        27                    1576          1543            33             98%
  3                *AKT3*        chr1         30                    1624          1624            0              100%
  4                *ARID1A*      chr1         76                    7058          6023            1035           85%
  5                *ARID1B*      chr6         75                    6950          5965            985            86%
  6                *ARID2*       chr12        71                    5718          5643            75             99%
  7                *ASCL4*       chr12        5                     532           382             150            72%
  8                *ATM*         chr11        147                   9791          9439            352            96%
  9                *BRAF*        chr7         37                    2481          2224            257            90%
  10               *CDKN2A*      chr9         9                     962           612             350            64%
  11               *COBL*        chr7         48                    4151          3977            174            96%
  12               *CREBBP*      chr16        96                    7639          7071            568            93%
  13               *CTNNB1*      chr3         32                    2486          2486            0              100%
  14               *CUL3*        chr2         42                    2561          2495            66             97%
  15               *EGFR*        chr7         60                    4189          4135            54             99%
  16               *EP300*       chr22        90                    7555          7182            373            95%
  17               *EPHA7*       chr6         44                    3175          3154            21             99%
  18               *ERBB2*       chr17        57                    4080          3808            272            93%
  19               *ERBB3*       chr12        59                    4440          4374            66             99%
  20               *FGFR1*       chr8         41                    2825          2816            9              100%
  21               *FGFR2*       chr10        43                    2910          2842            68             98%
  22               *FGFR3*       chr4         34                    2752          2215            537            81%
  23               *FOXP2*       chr7         36                    2487          2469            18             99%
  24               *HRAS*        chr11        11                    683           683             0              100%
  25               *KEAP1*       chr19        24                    1925          1845            80             96%
  26               *KMT2D*       chr12        192                   17,154        15,854          1300           92%
  27               *KRAS*        chr12        10                    737           681             56             92%
  28               *MAP2K1*      chr15        18                    1292          1239            53             96%
  29               *MET*         chr7         59                    4427          4396            31             99%
  30               *MGA*         chr15        110                   9428          9345            83             99%
  31               *MLL*         chr11        144                   12,279        11,875          404            97%
  32               *NF1*         chr17        136                   9161          9023            138            99%
  33               *NFE2L2*      chr2         23                    1868          1826            42             98%
  34               *NOTCH1*      chr9         99                    8008          7078            930            88%
  35               *NOTCH2*      chr1         101                   7809          7539            270            97%
  36               *NRAS*        chr1         9                     610           610             0              100%
  37               *PIK3CA*      chr3         50                    3407          3282            125            96%
  38               *PTEN*        chr10        18                    1302          1223            79             94%
  39               *RASA1*       chr5         55                    3412          3216            196            94%
  40               *RB1*         chr13        55                    3057          2902            155            95%
  41               *RBM10*       chrX         48                    3228          3079            149            95%
  42               *RIT1*        chr1         13                    771           771             0              100%
  43               *SETD2*       chr3         91                    7905          7663            242            97%
  44               *SLIT2*       chr4         76                    4972          4854            118            98%
  45               *SMAD4*       chr18        24                    1769          1715            54             97%
  46               *SMARCA4*     chr19        74                    5399          5055            344            94%
  47               *SOX2*        chr3         9                     964           883             81             92%
  48               *STK11*       chr19        23                    1392          1343            49             97%
  49               *TP53*        chr17        22                    1383          1351            32             98%
  50               *TP63*        chr3         34                    2360          2227            133            94%
  51               *TSC1*        chr9         49                    3705          3603            102            97%
  52               *TSC2*        chr16        92                    5834          5677            157            97%
  53               *U2AF1*       chr21        15                    880           870             10             99%

###### 

Summary of mapping sequencing reads and coverage data.

Table 3

  Sample name   Mapped reads   On target   Coverage depth   Uniformity
  ------------- -------------- ----------- ---------------- ------------
  Tumor         4,542,280      96.72%      1644             84.64%
  BrW/ppt       3,482,251      97.14%      1271             70.13%
  BrW/Sup       3,647,609      95.95%      1357             82.41%
  Buffy Coat    4,512,224      97.44%      1722             84.85%
  Plasma        4,127,207      83.04%      1286             74.97%
  Sputum        7,431,995      94.60%      2731             85.07%

Abbreviations: BrW/ppt = bronchial washing precipitates.

BrW/Sup = bronchial washing supernatant.

###### 

Detection of somatic mutations in primary lung tumor, bronchial washing samples, sputum and plasma.

Table 4

  Sample name   Mutations         Histological diagnosis   
  ------------- ----------------- ------------------------ ----------------
  Tumor         81.7% (277/339)   14.8% (293/1979)         Adenocarcinoma
  BrW/Sup       21.5% (85/414)    4.5% (90/1985)           Negative
  Sputum        7.3% (93/1282)    3.6% (72/1985)           Not applicable
  Plasma        2.4% (10/415)     1.8% (37/2010)           Not applicable
  BrW/ppt       Not detected      Not detected             Negative
  Buffy Coat    Not detected      Not detected             Not applicable

Abbreviations: AF = allelic fraction; Var: variant.

BrW/ppt = bronchial washing precipitates.

BrW/Sup = bronchial washing supernatant.
